NCT05126342 2025-04-06
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
AGO Research GmbH
Phase 2 Withdrawn
Clinical Trials
4 trialsNCT06385548 2025-04-01
LiDer
Vall d'Hebron Institute of Oncology
Phase 1/2 Withdrawn
NCT05405192 2023-02-28
Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia
University of Miami
Phase 2 Withdrawn
NCT03806049 2021-07-15
Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 3 Withdrawn